Source-defined biomarker
AAVRh74var capsid neutralizing antibodies
This exact source name has not been reconciled to a broader biomarker identity.
AAVRh74var capsid neutralizing antibodies is a source-defined biomarker in the evidence tier "FDA companion diagnostic". This page lists evidence by type: FDA companion diagnostic assertions (1), each linked to its source.
Source-scoped identity
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
FDA companion diagnostic
An FDA-cleared or approved companion diagnostic names this biomarker.
Source-level evidence only
Gene-level evidence mining does not apply to this kind of biomarker, so the source assertions on this page are the full depth available for it. A section missing below was not measured, and does not mean zero evidence.
FDA companion diagnostic assertions (1)
Shown in this order: most recent decision first.
| Diagnostic | Source biomarker wording | Manufacturer | Indication | Decision date |
|---|---|---|---|---|
| nAbCyte Anti-AAVRh74var HB-FE Assay | AAVRh74var capsid neutralizing antibodies | Labcorp Drug Development | Moderate to severe Hemophilia B patients | 2024-04-25 |
Not on this page
Checked, with nothing recorded for this biomarker: fda biomarker qualification projects and assay-provider ledger.